Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new ...

Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...

Autoimmune diseases are on the rise. It’s not just a hunch—autoimmune diseases are rising sharply, and the numbers are too significant to ignore. These chronic conditions, where the immune system ...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as ...

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as ...

Delivered record total revenue of $17.2 million, representing a 38% increase compared to the third quarter of 2024, or a 26% increase before the impact of one-time adjustments recorded in 2024. Grew ...